Piramal Pharma Acquires Additional 40.67% Stake in Yapan Bio for Rs 76 Crore, Takes 74% Ownership
The deal gives Piramal Pharma 74% ownership and expands its contract development and manufacturing services for vaccines, biologics and antibody-drug conjugates.
7 Articles
7 Articles
Piramal Pharma Acquires Additional 40.67% Stake in Yapan Bio for Rs 76 Crore, Takes 74% Ownership
Mumbai: Piramal Pharma Ltd. has completed the acquisition of an additional 40.67% stake in Yapan Bio Private Limited, a Hyderabad-based contract development and manufacturing organization (CDMO)...
Yapan Bio Private Limited specializes in process development, characterization, and manufacturing services that comply with good manufacturing practices...
Piramal Pharma acquires controlling 40 per cent stake in Yapan Bio
MUMBAI, India, Aug. 19, 2026 /PRNewswire/ -- Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) ("PPL) has completed the acquisition of an incremental 40.67% stake in Yapan Bio Private Limited ("Yapan Bio"), a Hyderabad-based CDMO specializing in vaccines and biologics for an aggregate cash consideration of ₹76 crore, or $7.95M USD. As a result of this transaction, PPL now owns 74% of Yapan Bio's equity, making Yapan Bio a subsidiary of PPL. Fin…
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
